National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Isavuconazole (Cresemba®) is indicated in adults for the treatment of mucormycosis in patients for whom amphotericin B is inappropriate.

Rapid Review

Commenced Completed Outcome
11/04/2016 11/05/2016 Full Pharmacoeconomic Evaluation Not Recommended.

 

The HSE has approved reimbursement following confidential price negotiations: April 2018